サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1423390

ヒトインスリン市場レポート：製品タイプ、流通チャネル、疾患タイプ、地域別、2024年～2032年

Human Insulin Market Report by Product Type (Drugs, Delivery Devices), Distribution Channel (Retail Pharmacies, Hospital Pharmacies, Online Retail Stores, and Others), Disease Type (Type I Diabetes, Type II Diabetes), and Region 2024-2032
出版日: | 発行: IMARC | ページ情報: 英文 149 Pages | 納期: 2～3営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　 詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=156.53円
ヒトインスリン市場レポート：製品タイプ、流通チャネル、疾患タイプ、地域別、2024年～2032年
出版日: 2024年01月30日
発行: IMARC
ページ情報: 英文 149 Pages
納期: 2～3営業日
  • 全表示
  • 概要
  • 図表
  • 目次
概要

ヒトインスリンの世界市場規模は2023年に482億米ドルに達しました。今後、IMARC Groupは、2024年から2032年にかけて6.2%の成長率（CAGR）を示し、2032年までに842億米ドルに達すると予測しています。糖尿病罹患率の増加、老年人口の増加、ヒトインスリン製剤の急速な進歩、広範な研究開発活動、政府による支援政策の実施は、市場を推進している主な要因の一部です。

ヒトインスリンは、人体内のグルコース代謝の重要な調節因子として機能するペプチドホルモンを指します。膵臓のβ細胞によって産生され、正常な血糖値の維持に基本的な役割を果たしています。ヒトインスリンは、短時間作用型、中間作用型、長時間作用型など様々な剤形があります。1型糖尿病、糖尿病性ケトアシドーシス（DKA）、妊娠糖尿病、2型糖尿病の管理に広く使用されています。最適な血糖コントロールを達成し、糖尿病に伴う長期合併症のリスクを最小化するのに役立ちます。ヒトインスリンはまた、体内の自然なインスリン産生を忠実に模倣しているため、安全性と有効性のプロファイルが向上しています。

糖尿病治療に関する認識を高め、質の高いヘルスケア施設へのアクセスを提供するための政府の支援政策の実施が、市場の成長に寄与しています。さらに、個別化医療や精密治療への移行動向は、投与量の調整やカスタマイズされたインスリンレジメンを可能にし、患者の転帰を改善することから、製品需要を促進しています。このほか、ブランドの認知度を向上させ、認知度を高め、新規顧客を獲得するためのメーカーによる積極的なマーケティングやプロモーション活動が、市場の成長を後押ししています。さらに、ヒトインスリンの重要性に関する大衆の意識と教育の高まりが、市場の成長を支えています。その他にも、ヘルスケアインフラの急速な拡大、先進的な生産方法の開発への投資の増加、主要企業間のパートナーシップの拡大などが、市場成長を促進すると予測されています。

ヒトインスリン市場の動向と促進要因：

糖尿病の増加

ヒトインスリンは、血糖値の上昇を特徴とする慢性代謝疾患である糖尿病の治療と管理において重要な役割を果たしています。インスリンの補充、個別化治療、特定の病態の管理に広く使用されています。さらに、1型糖尿病治療において、体内で生成できない必要なインスリンを供給し、血糖値の調節を助け、高血糖を予防するために製品が広く利用されていることが、市場の成長を支えています。さらに、体内のインスリン供給を補い、グルコース利用を改善するために経口薬として服用されます。これとは別に、健康な膵臓の基礎インスリン分泌を模倣して、一日中インスリンを継続的に供給するためのインスリンポンプ療法における製品採用の増加が、市場の成長に寄与しています。さらに、ヒトインスリンは、グルコースの変動を防ぎ、外科的合併症のリスクを軽減するために、術前およびクリティカルケア設定において重要な役割を果たしています。

老年人口の増加

ヒトインスリンは、糖尿病を患う老年人口において最適な血糖コントロールを達成する上で重要な役割を果たしています。ヒトインスリン製剤は、年齢、病歴、腎機能、全般的な健康状態などの要因に基づいて、高齢者特有のニーズを満たすための個別化治療と正確な投与量調整を可能にします。さらに、ヒト・インスリン製剤は安全性が確立されており、糖尿病治療において数十年にわたって使用されてきたため、新しい治療法に比べて高齢者集団にとってリスクが少ないです。さらに、他の糖尿病治療薬と比較して、高齢者における低血糖のリスクを最小限に抑えることができます。これとは別に、ヒトインスリンは、インスリンペン、シリンジ、インスリンポンプを含む様々な方法で投与することができ、ヘルスケアプロバイダーは、老人のニーズや好みに基づいて最も適切なインスリン送達方法を選択することができます。

ヒト・インスリン製剤の急速な進歩

組換えデオキシリボ核酸（DNA）技術のイントロダクションは、動物由来のインスリン抽出の必要性を排除し、より安定した信頼性の高いインスリン源を提供するもので、市場成長にプラスの影響を与えています。さらに、インスリンの連続的で中断のない生産を可能にすることで効率性と生産性を向上させ、時間の短縮、コストの節約、需要の変化への迅速な対応を可能にする連続製造プロセスの活用が、市場の成長に寄与しています。さらに、発酵条件、培地処方、細胞培養プロセスの最適化など、高い製品品質を維持しながら生産コストを削減するのに役立つバイオプロセス技術の最近の進歩が、市場の成長を支えています。さらに、インスリン精製の効率と効果を改善するために、クロマトグラフィー、ろ過、アフィニティーベースの分離などの高度な処理技術を統合することが、市場の成長を強化しています。

目次

第1章 序文

第2章 調査範囲と調査手法

  • 調査目的
  • 利害関係者
  • データソース
    • 一次情報
    • 二次情報
  • 市場推定
    • ボトムアップアプローチ
    • トップダウンアプローチ
  • 調査手法

第3章 エグゼクティブサマリー

第4章 イントロダクション

  • 概要
  • 主要産業動向

第5章 ヒトインスリンの世界市場

  • 市場概要
  • 市場実績
  • COVID-19の影響
  • 市場予測

第6章 市場内訳：製品タイプ別

  • 医薬品
    • 市場動向
    • 市場内訳：タイプ別
      • ヒト型インスリンアナログ製剤およびバイオシミラー製剤
        • 速効型
        • 市場動向
        • 市場予測
        • 長時間作用型
        • 市場動向
        • 市場予測
        • プレミックス
        • 市場動向
        • 市場予測
      • ヒトインスリン生物製剤
        • 短時間作用型
        • 市場動向
        • 市場予測
        • 中間作用型
        • 市場動向
        • 市場予測
        • プレミックス
        • 市場動向
        • 市場予測
    • 市場予測
  • デリバリーデバイス
    • 市場動向
    • 市場内訳：タイプ別
      • ペン
        • 再利用可能ペン
        • 使い捨てペン
      • ペンニードル
        • 標準ペンニードル
        • 安全ペンニードル
      • 注射器
      • その他
    • 市場予測

第7章 市場内訳：流通チャネル別

  • 小売薬局
    • 市場動向
    • 市場予測
  • 病院薬局
    • 市場動向
    • 市場予測
  • オンライン小売店
    • 市場動向
    • 市場予測
  • その他
    • 市場動向
    • 市場予測

第8章 市場内訳：疾患タイプ別

  • I型糖尿病
    • 市場動向
    • 市場予測
  • II型糖尿病
    • 市場動向
    • 市場予測

第9章 市場内訳：地域別

  • 北米
    • 米国
      • 市場動向
      • 市場予測
    • カナダ
      • 市場動向
      • 市場予測
  • アジア太平洋
    • 中国
      • 市場動向
      • 市場予測
    • 日本
      • 市場動向
      • 市場予測
    • インド
      • 市場動向
      • 市場予測
    • 韓国
      • 市場動向
      • 市場予測
    • オーストラリア
      • 市場動向
      • 市場予測
    • インドネシア
      • 市場動向
      • 市場予測
    • その他
      • 市場動向
      • 市場予測
  • 欧州
    • ドイツ
      • 市場動向
      • 市場予測
    • フランス
      • 市場動向
      • 市場予測
    • 英国
      • 市場動向
      • 市場予測
    • イタリア
      • 市場動向
      • 市場予測
    • スペイン
      • 市場動向
      • 市場予測
    • ロシア
      • 市場動向
      • 市場予測
    • その他
      • 市場動向
      • 市場予測
  • ラテンアメリカ
    • ブラジル
      • 市場動向
      • 市場予測
    • メキシコ
      • 市場動向
      • 市場予測
    • その他
      • 市場動向
      • 市場予測
  • 中東・アフリカ
    • 市場動向
    • 市場内訳：国別
    • 市場予測

第10章 SWOT分析

  • 概要
  • 強み
  • 弱み
  • 機会
  • 脅威

第11章 バリューチェーン分析

第12章 ポーターのファイブフォース分析

  • 概要
  • 買い手の交渉力
  • 供給企業の交渉力
  • 競合の程度
  • 新規参入業者の脅威
  • 代替品の脅威

第13章 価格指標

第14章 競合情勢

  • 市場構造
  • 主要企業
  • 主要企業のプロファイル
    • B. Braun Melsungen AG
    • Becton, Dickinson and Company（BD）
    • Biocon
    • Eli Lilly and Company
    • Gulf Pharmaceutical Industries（Julphar）
    • Novo Nordisk A/S
    • Pfizer Inc.
    • Groupe Sanofi
    • SEDICO Co.
    • Wockhardt Limited
    • Ypsomed AG
図表

List of Figures

  • Figure 1: Global: Human Insulin Market: Major Drivers and Challenges
  • Figure 2: Global: Human Insulin Market: Sales Value (in Billion US$), 2018-2023
  • Figure 3: Global: Human Insulin Market: Breakup by Product Type (in %), 2023
  • Figure 4: Global: Human Insulin Drugs Market: Breakup by Type (in %), 2023
  • Figure 5: Global: Human Insulin Delivery Devices Market: Breakup by Type (in %), 2023
  • Figure 6: Global: Human Insulin Market: Breakup by Distribution Channel (in %), 2023
  • Figure 7: Global: Human Insulin Market: Breakup by Disease Type (in %), 2023
  • Figure 8: Global: Human Insulin Market: Breakup by Region (in %), 2023
  • Figure 9: Global: Human Insulin Market Forecast: Sales Value (in Billion US$), 2024-2032
  • Figure 10: Global: Human Insulin (Drugs) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 11: Global: Human Insulin Drugs (Analogs and Biosimilars) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 12: Global: Human Insulin Drugs (Analogs and Biosimilars- Rapid Acting) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 13: Global: Human Insulin Drugs (Analogs and Biosimilars- Rapid Acting) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 14: Global: Human Insulin Drugs (Analogs and Biosimilars- Long Acting) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 15: Global: Human Insulin Drugs (Analogs and Biosimilars- Long Acting) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 16: Global: Human Insulin Drugs (Analogs and Biosimilars- Premixed) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 17: Global: Human Insulin Drugs (Analogs and Biosimilars- Premixed) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 18: Global: Human Insulin Drugs (Analogs and Biosimilars) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 19: Global: Human Insulin Drugs (Biologics) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 20: Global: Human Insulin Drugs (Biologics - Short Acting) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 21: Global: Human Insulin Drugs (Biologics - Short Acting) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 22: Global: Human Insulin Drugs (Biologics - Intermediate Acting) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 23: Global: Human Insulin Drugs (Biologics - Intermediate Acting) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 24: Global: Human Insulin Drugs (Biologics - Premixed) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 25: Global: Human Insulin Drugs (Biologics - Premixed) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 26: Global: Human Insulin Drugs (Biologics) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 27: Global: Human Insulin (Drugs) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 28: Global: Human Insulin (Delivery Devices) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 29: Global: Human Insulin Delivery Devices (Pens) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 30: Global: Human Insulin Delivery Devices (Pens) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 31: Global: Human Insulin Delivery Devices (Pen Needles) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 32: Global: Human Insulin Delivery Devices (Pen Needles) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 33: Global: Human Insulin Delivery Devices (Syringes) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 34: Global: Human Insulin Delivery Devices (Syringes) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 35: Global: Human Insulin Delivery Devices (Others) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 36: Global: Human Insulin Delivery Devices (Others) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 37: Global: Human Insulin (Delivery Devices) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 38: Global: Human Insulin Market: Sales through Retail Pharmacies (in Million US$), 2018 & 2023
  • Figure 39: Global: Human Insulin Market Forecast: Sales through Retail Pharmacies (in Million US$), 2024-2032
  • Figure 40: Global: Human Insulin Market: Sales through Hospital Pharmacies (in Million US$), 2018 & 2023
  • Figure 41: Global: Human Insulin Market Forecast: Sales through Hospital Pharmacies (in Million US$), 2024-2032
  • Figure 42: Global: Human Insulin Market: Sales through Online Retail Stores (in Million US$), 2018 & 2023
  • Figure 43: Global: Human Insulin Market Forecast: Sales through Online Retail Stores (in Million US$), 2024-2032
  • Figure 44: Global: Human Insulin Market: Sales through Other Distribution Channels (in Million US$), 2018 & 2023
  • Figure 45: Global: Human Insulin Market Forecast: Sales through Other Distribution Channels (in Million US$), 2024-2032
  • Figure 46: Global: Human Insulin (Type I Diabetes) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 47: Global: Human Insulin (Type I Diabetes) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 48: Global: Human Insulin (Type II Diabetes) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 49: Global: Human Insulin (Type II Diabetes) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 50: North America: Human Insulin Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 51: North America: Human Insulin Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 52: United States: Human Insulin Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 53: United States: Human Insulin Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 54: Canada: Human Insulin Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 55: Canada: Human Insulin Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 56: Asia Pacific: Human Insulin Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 57: Asia Pacific: Human Insulin Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 58: China: Human Insulin Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 59: China: Human Insulin Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 60: Japan: Human Insulin Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 61: Japan: Human Insulin Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 62: India: Human Insulin Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 63: India: Human Insulin Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 64: South Korea: Human Insulin Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 65: South Korea: Human Insulin Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 66: Australia: Human Insulin Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 67: Australia: Human Insulin Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 68: Indonesia: Human Insulin Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 69: Indonesia: Human Insulin Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 70: Others: Human Insulin Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 71: Others: Human Insulin Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 72: Europe: Human Insulin Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 73: Europe: Human Insulin Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 74: Germany: Human Insulin Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 75: Germany: Human Insulin Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 76: France: Human Insulin Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 77: France: Human Insulin Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 78: United Kingdom: Human Insulin Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 79: United Kingdom: Human Insulin Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 80: Italy: Human Insulin Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 81: Italy: Human Insulin Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 82: Spain: Human Insulin Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 83: Spain: Human Insulin Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 84: Russia: Human Insulin Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 85: Russia: Human Insulin Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 86: Others: Human Insulin Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 87: Others: Human Insulin Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 88: Latin America: Human Insulin Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 89: Latin America: Human Insulin Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 90: Brazil: Human Insulin Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 91: Brazil: Human Insulin Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 92: Mexico: Human Insulin Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 93: Mexico: Human Insulin Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 94: Others: Human Insulin Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 95: Others: Human Insulin Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 96: Middle East and Africa: Human Insulin Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 97: Middle East and Africa: Human Insulin Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 98: Global: Human Insulin Industry: SWOT Analysis
  • Figure 99: Global: Human Insulin Industry: Value Chain Analysis
  • Figure 100: Global: Human Insulin Industry: Porter's Five Forces Analysis

List of Tables

  • Table 1: Global: Human Insulin Market: Key Industry Highlights, 2023 and 2032
  • Table 2: Global: Human Insulin Market Forecast: Breakup by Product Type (in Million US$), 2024-2032
  • Table 3: Global: Human Insulin Drugs Market Forecast: Breakup by Type (in Million US$), 2024-2032
  • Table 4: Global: Human Insulin Delivery Devices Market Forecast: Breakup by Type (in Million US$), 2024-2032
  • Table 5: Global: Human Insulin Market Forecast: Breakup by Distribution Channel (in Million US$), 2024-2032
  • Table 6: Global: Human Insulin Market Forecast: Breakup by Disease Type (in Million US$), 2024-2032
  • Table 7: Global: Human Insulin Market Forecast: Breakup by Region (in Million US$), 2024-2032
  • Table 8: Global: Human Insulin Market: Competitive Structure
  • Table 9: Global: Human Insulin Market: Key Players
目次
Product Code: SR112024A1950

Abstract

The global human insulin market size reached US$ 48.2 Billion in 2023. Looking forward, IMARC Group expects the market to reach US$ 84.2 Billion by 2032, exhibiting a growth rate (CAGR) of 6.2% during 2024-2032. The growing incidences of diabetes, rising geriatric population, rapid advancements in human insulin production, extensive research and development (R&D) activities, and the implementation of supportive government policies are some of the major factors propelling the market.

Human insulin refers to a peptide hormone that serves as a vital regulator of glucose metabolism within the human body. It is produced by pancreatic beta cells and plays a fundamental role in maintaining normal blood sugar levels. Human insulin is available in various forms, including short-acting, intermediate-acting, and long-acting formulations. It is widely used for the management of type 1 diabetes, diabetic ketoacidosis (DKA), gestational diabetes, and type 2 diabetes. It aids in achieving optimal blood glucose control and minimizing the risk of long-term complications associated with the disease. Human insulin also offers enhanced safety and efficacy profile, as it closely mimics the body's natural insulin production.

The implementation of supportive government policies to increase awareness regarding diabetes treatment and provide access to high-quality healthcare facilities is contributing to the market growth. Furthermore, the shifting trends towards personalized medicine and precision therapies are facilitating product demand as it allows dosage adjustments and customized insulin regimens, which improves patient outcomes. Besides this, aggressive marketing and promotional activities by manufacturers to improve brand visibility, increase awareness, and attract new customers are propelling the market growth. Moreover, the growing awareness and education among the masses regarding the importance of human insulin is supporting the market growth. Other factors, including the rapid expansion of the healthcare infrastructure, increasing investment in developing advanced production methods, and growing partnerships between key players, are anticipated to drive the market growth.

Human Insulin Market Trends/Drivers:

The growing incidences of diabetes

Human insulin plays a vital role in the treatment and management of diabetes, a chronic metabolic disorder characterized by elevated blood sugar levels. It is widely used in insulin replacement, individualized therapy, and the management of specific conditions. Furthermore, the widespread product utilization in type 1 diabetes treatment to provide necessary insulin that bodies cannot produce, thus aiding in regulating blood sugar levels and preventing hyperglycemia, is supporting the market growth. Additionally, it is taken as an oral medication to supplement the body's insulin supply and improve glucose utilization. Apart from this, the rising product adoption in insulin pump therapy to deliver a continuous supply of insulin throughout the day, mimicking the basal insulin secretion of a healthy pancreas, is contributing to the market growth. Moreover, human insulin plays a critical role in preoperative and critical care settings to prevent glucose fluctuations and reduce the risks of surgical complications.

The rising geriatric population

Human insulin plays a crucial role in achieving optimal glycemic control in the geriatric population suffering from diabetes. It allows for individualized therapy and precise dosage adjustments to meet the specific needs of aging individuals based on factors such as age, medical history, renal function, and overall health status. Furthermore, human insulin has a well-established safety profile and has been used for decades in the treatment of diabetes, making it less risky for the geriatric population compared to newer treatments. Additionally, it aids in minimizing the risk of hypoglycemia in the elderly population compared to certain other diabetes medications. Apart from this, human insulin can be administered through various methods, including insulin pens, syringes, and insulin pumps, which allows healthcare providers to choose the most appropriate insulin delivery method based on the needs and preferences of geriatric individuals.

Rapid advancements in human insulin production

The introduction of recombinant deoxyribonucleic acid (DNA) technology, which eliminates the need for animal-based insulin extraction and provides a more consistent and reliable source of insulin, is positively influencing the market growth. Furthermore, the utilization of a continuous manufacturing process, which improves efficiency and productivity by allowing continuous and uninterrupted production of insulin, reducing time, saving cost, and enabling rapid response to changes in demand, is contributing to the market growth. Additionally, the recent advancements in bioprocessing techniques, such as the optimization of fermentation conditions, media formulation, and cell culture processes, which aid in reducing production costs while maintaining high product quality, are supporting the market growth. Moreover, the integration of advanced processing techniques, such as chromatography, filtration, and affinity-based separations, to improve the efficiency and effectiveness of insulin purification is strengthening the market growth.

Human Insulin Industry Segmentation:

IMARC Group provides an analysis of the key trends in each segment of the global human insulin market report, along with forecasts at the global, regional, and country levels from 2024-2032. Our report has categorized the market based on product type, distribution channel, and disease type.

Breakup by Product Type:

Drugs

Human Insulin Analogs and Biosimilars

Rapid Acting

Long Acting

Premixed

Human Insulin Biologics

Short Acting

Intermediate Acting

Premixed

Delivery Devices

Pens

Reusable Pens

Disposable Pens

Pen Needles

Standard Pen Needles

Safety Pen Needles

Syringes

Others

Drugs dominate the market

The report has provided a detailed breakup and analysis of the market based on the product type. This includes drugs (human insulin analogs and biosimilars (rapid acting, long acting, and premixed) and human insulin biologics (short acting, intermediate acting, and premixed)) and delivery devices (pens (reusable pens and disposable pens), pen needles (standard pen needles and safety pen needles), syringes, and others). According to the report, drugs represented the largest market segment.

Drugs are dominating the market growth as they have been extensively researched and proven to be effective in managing diabetes. Furthermore, their established market presence has created familiarity and confidence among prescribers, leading to their continued dominance. Apart from this, human insulin drugs are generally more accessible and affordable compared to newer, patented insulin alternatives. Their easy accessibility and affordability have contributed to the widespread use of these drugs, particularly in resource-limited settings. Besides this, they have received regulatory approvals from health authorities around the world, which ensure that human insulin drugs meet quality standards and efficacy requirements. Moreover, human insulin drugs have been widely accepted by patients with diabetes due to their long history of use and proven effectiveness.

Breakup by Distribution Channel:

Retail Pharmacies

Hospital Pharmacies

Online Retail Stores

Others

Retail Pharmacies dominate the market

The report has provided a detailed breakup and analysis of the market based on the distribution channel. This includes retail pharmacies, hospital pharmacies, online retail stores, and others. According to the report, the distribution channel represented the largest market segment.

Retail pharmacies are situated in easily accessible locations, such as shopping centers, neighborhoods, and urban areas, which makes it convenient for patients with diabetes to access their prescribed medications. Furthermore, they have an extensive network of stores with multiple locations across cities, regions, and countries, which ensures that patients can find a nearby retail pharmacy to fill their human insulin prescriptions, irrespective of their location. Additionally, retail pharmacies have established relationships with various insurance providers and government healthcare programs, allowing for smooth reimbursement processes. Moreover, they provide additional services beyond prescription dispensing, including the proper use of human insulin, injection techniques, blood glucose monitoring, and lifestyle modifications.

Breakup by Disease Type:

Type I Diabetes

Type II Diabetes

Type I diabetes holds the largest market share

The report has provided a detailed breakup and analysis of the market based on the disease type. This includes type I and type II diabetes. According to the report, type I diabetes represented the largest market segment.

Type 1 diabetes holds the majority market share owing to its widespread prevalence across the globe. Furthermore, individuals with type 1 diabetes require insulin from the time of diagnosis throughout their lives. This substantial need for human insulin necessitates its steady supply to meet the rising demand for insulin replacement therapy. Furthermore, the absence of natural insulin production in type 1 diabetes creates a significant market demand as the primary source of insulin replacement. Along with this, human insulin provides a closer match to the insulin needs of individuals with type 1 diabetes compared to other insulin analogs, as it is structurally identical to the insulin naturally produced in the human body.

Breakup by Region:

North America

United States

Canada

Asia Pacific

China

Japan

India

South Korea

Australia

Indonesia

Others

Europe

Germany

France

United Kingdom

Italy

Spain

Russia

Others

Latin America

Brazil

Mexico

Others

Middle East and Africa

North America exhibits a clear dominance in the market, accounting for the largest human insulin market share

The report has also provided a comprehensive analysis of all the major regional markets, which includes North America (the United States and Canada); Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, and others); Europe (Germany, France, the United Kingdom, Italy, Spain, Russia, and others); Latin America (Brazil, Mexico, and others); and the Middle East and Africa. According to the report, North America represented the largest market segment.

North America is dominating the market as it has a significant burden of diabetes, with both type 1 and type 2 diabetes being prevalent in the region. Furthermore, it boasts a well-developed healthcare infrastructure characterized by advanced medical facilities, research institutions, and pharmaceutical companies, which supports the production, distribution, and accessibility of human insulin. Additionally, North America is at the forefront of technological advancements in the healthcare sector, including the development of innovative insulin delivery systems, such as insulin pens and insulin pumps, which enhance the administration and effectiveness of human insulin. Moreover, the presence of several leading pharmaceutical companies that are actively engaged in the production and distribution of human insulin is acting as another growth-inducing factor. Apart from this, North America has well-established regulatory bodies which ensure the safety, efficacy, and quality of pharmaceutical products, including human insulin.

Competitive Landscape:

The leading companies in the market are investing in research and development (R&D) projects to create innovative human insulin products. They are focusing on improving the pharmacokinetics, delivery systems, and formulations of insulin to enhance patient convenience and adherence. Apart from this, companies are expanding their presence in emerging markets due to the growing diabetic population and increasing healthcare access. Additionally, they are establishing partnerships with local distributors, healthcare providers, and regulatory authorities to navigate the regulatory landscape and ensure the availability of their human insulin products. Moreover, several key players are developing a range of insulin formulations with varying durations of action, which allows them to capture a broader market share and meet the specific requirements of patients with different types of diabetes.

The report has provided a comprehensive analysis of the competitive landscape in the market. Detailed profiles of all major companies have also been provided. Some of the key players in the market include:

B. Braun Melsungen AG

Becton

Dickinson and Company (BD)

Biocon

Eli Lilly and Company

Gulf Pharmaceutical Industries (Julphar)

Novo Nordisk A/S

Pfizer Inc.

Groupe Sanofi

SEDICO Co.

Wockhardt Limited

Ypsomed AG

Recent Developments:

In December 2021, Dickinson and Company (BD) announced that "embecta" will be the name of the publicly-traded company that will hold BD's Diabetes Care business.

In November 2022, Biocon Sdn. Bhd., a subsidiary of Biocon in Malaysia, announced that it had been awarded a three-year contract for its recombinant human insulin brand Insugen, by the Ministry of Health (MoH), Malaysia.

In February 2023, Eli Lilly and Company announced a partnership with International Agencies (Bangladesh) Ltd. (IABL) to ensure access to high-quality, affordable insulin in Bangladesh.

Key Questions Answered in This Report

  • 1. What was the size of the global human insulin market in 2023?
  • 2. What is the expected growth rate of the global human insulin market during 2024-2032?
  • 3. What are the key factors driving the global human insulin market?
  • 4. What has been the impact of COVID-19 on the global human insulin market?
  • 5. What is the breakup of the global human insulin market based on the product type?
  • 6. What is the breakup of the global human insulin market based on the distribution channel?
  • 7. What is the breakup of the global human insulin market based on the disease type?
  • 8. What are the key regions in the global human insulin market?
  • 9. Who are the key players/companies in the global human insulin market?

Table of Contents

1 Preface

2 Scope and Methodology

  • 2.1 Objectives of the Study
  • 2.2 Stakeholders
  • 2.3 Data Sources
    • 2.3.1 Primary Sources
    • 2.3.2 Secondary Sources
  • 2.4 Market Estimation
    • 2.4.1 Bottom-Up Approach
    • 2.4.2 Top-Down Approach
  • 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

  • 4.1 Overview
  • 4.2 Key Industry Trends

5 Global Human Insulin Market

  • 5.1 Market Overview
  • 5.2 Market Performance
  • 5.3 Impact of COVID-19
  • 5.4 Market Forecast

6 Market Breakup by Product Type

  • 6.1 Drugs
    • 6.1.1 Market Trends
    • 6.1.2 Market Breakup by Type
      • 6.1.2.1 Human Insulin Analogs and Biosimilars
        • 6.1.2.1.1 Rapid Acting
        • 6.1.2.1.1.1 Market Trends
        • 6.1.2.1.1.2 Market Forecast
        • 6.1.2.1.2 Long Acting
        • 6.1.2.1.2.1 Market Trends
        • 6.1.2.1.2.2 Market Forecast
        • 6.1.2.1.3 Premixed
        • 6.1.2.1.3.1 Market Trends
        • 6.1.2.1.3.2 Market Forecast
      • 6.1.2.2 Human Insulin Biologics
        • 6.1.2.2.1 Short Acting
        • 6.1.2.2.1.1 Market Trends
        • 6.1.2.2.1.2 Market Forecast
        • 6.1.2.2.2 Intermediate Acting
        • 6.1.2.2.2.1 Market Trends
        • 6.1.2.2.2.2 Market Forecast
        • 6.1.2.2.3 Premixed
        • 6.1.2.2.3.1 Market Trends
        • 6.1.2.2.3.2 Market Forecast
    • 6.1.3 Market Forecast
  • 6.2 Delivery Devices
    • 6.2.1 Market Trends
    • 6.2.2 Market Breakup by Type
      • 6.2.2.1 Pens
        • 6.2.2.1.1 Reusable Pens
        • 6.2.2.1.2 Disposable Pens
      • 6.2.2.2 Pen Needles
        • 6.2.2.2.1 Standard Pen Needles
        • 6.2.2.2.2 Safety Pen Needles
      • 6.2.2.3 Syringes
      • 6.2.2.4 Others
    • 6.2.3 Market Forecast

7 Market Breakup by Distribution Channel

  • 7.1 Retail Pharmacies
    • 7.1.1 Market Trends
    • 7.1.2 Market Forecast
  • 7.2 Hospital Pharmacies
    • 7.2.1 Market Trends
    • 7.2.2 Market Forecast
  • 7.3 Online Retail Stores
    • 7.3.1 Market Trends
    • 7.3.2 Market Forecast
  • 7.4 Others
    • 7.4.1 Market Trends
    • 7.4.2 Market Forecast

8 Market Breakup by Disease Type

  • 8.1 Type I Diabetes
    • 8.1.1 Market Trends
    • 8.1.2 Market Forecast
  • 8.2 Type II Diabetes
    • 8.2.1 Market Trends
    • 8.2.2 Market Forecast

9 Market Breakup by Region

  • 9.1 North America
    • 9.1.1 United States
      • 9.1.1.1 Market Trends
      • 9.1.1.2 Market Forecast
    • 9.1.2 Canada
      • 9.1.2.1 Market Trends
      • 9.1.2.2 Market Forecast
  • 9.2 Asia Pacific
    • 9.2.1 China
      • 9.2.1.1 Market Trends
      • 9.2.1.2 Market Forecast
    • 9.2.2 Japan
      • 9.2.2.1 Market Trends
      • 9.2.2.2 Market Forecast
    • 9.2.3 India
      • 9.2.3.1 Market Trends
      • 9.2.3.2 Market Forecast
    • 9.2.4 South Korea
      • 9.2.4.1 Market Trends
      • 9.2.4.2 Market Forecast
    • 9.2.5 Australia
      • 9.2.5.1 Market Trends
      • 9.2.5.2 Market Forecast
    • 9.2.6 Indonesia
      • 9.2.6.1 Market Trends
      • 9.2.6.2 Market Forecast
    • 9.2.7 Others
      • 9.2.7.1 Market Trends
      • 9.2.7.2 Market Forecast
  • 9.3 Europe
    • 9.3.1 Germany
      • 9.3.1.1 Market Trends
      • 9.3.1.2 Market Forecast
    • 9.3.2 France
      • 9.3.2.1 Market Trends
      • 9.3.2.2 Market Forecast
    • 9.3.3 United Kingdom
      • 9.3.3.1 Market Trends
      • 9.3.3.2 Market Forecast
    • 9.3.4 Italy
      • 9.3.4.1 Market Trends
      • 9.3.4.2 Market Forecast
    • 9.3.5 Spain
      • 9.3.5.1 Market Trends
      • 9.3.5.2 Market Forecast
    • 9.3.6 Russia
      • 9.3.6.1 Market Trends
      • 9.3.6.2 Market Forecast
    • 9.3.7 Others
      • 9.3.7.1 Market Trends
      • 9.3.7.2 Market Forecast
  • 9.4 Latin America
    • 9.4.1 Brazil
      • 9.4.1.1 Market Trends
      • 9.4.1.2 Market Forecast
    • 9.4.2 Mexico
      • 9.4.2.1 Market Trends
      • 9.4.2.2 Market Forecast
    • 9.4.3 Others
      • 9.4.3.1 Market Trends
      • 9.4.3.2 Market Forecast
  • 9.5 Middle East and Africa
    • 9.5.1 Market Trends
    • 9.5.2 Market Breakup by Country
    • 9.5.3 Market Forecast

10 SWOT Analysis

  • 10.1 Overview
  • 10.2 Strengths
  • 10.3 Weaknesses
  • 10.4 Opportunities
  • 10.5 Threats

11 Value Chain Analysis

12 Porters Five Forces Analysis

  • 12.1 Overview
  • 12.2 Bargaining Power of Buyers
  • 12.3 Bargaining Power of Suppliers
  • 12.4 Degree of Competition
  • 12.5 Threat of New Entrants
  • 12.6 Threat of Substitutes

13 Price Indicators

14 Competitive Landscape

  • 14.1 Market Structure
  • 14.2 Key Players
  • 14.3 Profiles of Key Players
    • 14.3.1 B. Braun Melsungen AG
      • 14.3.1.1 Company Overview
      • 14.3.1.2 Product Portfolio
      • 14.3.1.3 SWOT Analysis
    • 14.3.2 Becton, Dickinson and Company (BD)
      • 14.3.2.1 Company Overview
      • 14.3.2.2 Product Portfolio
      • 14.3.2.3 Financials
      • 14.3.2.4 SWOT Analysis
    • 14.3.3 Biocon
      • 14.3.3.1 Company Overview
      • 14.3.3.2 Product Portfolio
      • 14.3.3.3 Financials
      • 14.3.3.4 SWOT Analysis
    • 14.3.4 Eli Lilly and Company
      • 14.3.4.1 Company Overview
      • 14.3.4.2 Product Portfolio
      • 14.3.4.3 Financials
      • 14.3.4.4 SWOT Analysis
    • 14.3.5 Gulf Pharmaceutical Industries (Julphar)
      • 14.3.5.1 Company Overview
      • 14.3.5.2 Product Portfolio
      • 14.3.5.3 Financials
      • 14.3.5.4 SWOT Analysis
    • 14.3.6 Novo Nordisk A/S
      • 14.3.6.1 Company Overview
      • 14.3.6.2 Product Portfolio
      • 14.3.6.3 Financials
      • 14.3.6.4 SWOT Analysis
    • 14.3.7 Pfizer Inc.
      • 14.3.7.1 Company Overview
      • 14.3.7.2 Product Portfolio
      • 14.3.7.3 Financials
      • 14.3.7.4 SWOT Analysis
    • 14.3.8 Groupe Sanofi
      • 14.3.8.1 Company Overview
      • 14.3.8.2 Product Portfolio
      • 14.3.8.3 Financials
      • 14.3.8.4 SWOT Analysis
    • 14.3.9 SEDICO Co.
      • 14.3.9.1 Company Overview
      • 14.3.9.2 Product Portfolio
    • 14.3.10 Wockhardt Limited
      • 14.3.10.1 Company Overview
      • 14.3.10.2 Product Portfolio
      • 14.3.10.3 Financials
    • 14.3.11 Ypsomed AG
      • 14.3.11.1 Company Overview
      • 14.3.11.2 Product Portfolio
      • 14.3.11.3 Financials
      • 14.3.11.4 SWOT Analysis